Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.53 +12.5%	$1.34	$0.86 ▼ $3.36	$82.38M	0.14	232,796 shs	919,417 shs
ANRO Alto Neuroscience	$3.91 +8.8%	$2.80	$1.60 ▼ $15.04	$97.21M	1.84	102,544 shs	157,542 shs
ATRA Atara Biotherapeutics	$12.34 +7.4%	$10.10	$5.01 ▼ $18.70	$80.69M	0.26	50,828 shs	90,718 shs
BCAB BioAtla	$0.36 -0.4%	$0.38	$0.24 ▼ $2.53	$21M	0.9	530,581 shs	504,140 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	+12.50%	+7.75%	-8.93%	+50.00%	-46.32%
ANRO Alto Neuroscience	+8.83%	+24.03%	+28.01%	+27.93%	-64.64%
ATRA Atara Biotherapeutics	+7.40%	+0.41%	+0.65%	+72.83%	+70.21%
BCAB BioAtla	-0.39%	-3.13%	-10.91%	-8.67%	-81.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	3.0614 of 5 stars	3.5	5.0	0.0	1.4	1.7	0.6
ANRO Alto Neuroscience	1.7374 of 5 stars	3.3	1.0	0.0	1.1	0.8	1.3
ATRA Atara Biotherapeutics	4.6717 of 5 stars	3.4	4.0	4.7	3.0	3.3	0.6
BCAB BioAtla	2.2968 of 5 stars	3.0	3.0	0.0	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$6.33	313.94% Upside
ANRO Alto Neuroscience	2.57	Moderate Buy	$8.50	117.56% Upside
ATRA Atara Biotherapeutics	2.80	Moderate Buy	$21.00	70.18% Upside
BCAB BioAtla	2.00	Hold	$5.00	1,303.71% Upside

Current Analyst Ratings Breakdown

Latest BCAB, ATRA, ABOS, and ANRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/13/2025	BCAB BioAtla	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
8/13/2025	BCAB BioAtla	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
6/26/2025	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.93 per share	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.56 per share	N/A
ATRA Atara Biotherapeutics	$128.94M	0.67	N/A	N/A	($4.99) per share	-2.47
BCAB BioAtla	$11M	1.90	N/A	N/A	($0.29) per share	-1.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-81.39%	-61.96%	11/11/2025 (Estimated)
ANRO Alto Neuroscience	-$61.43M	-$2.39	N/A	N/A	N/A	N/A	-44.34%	-36.73%	11/11/2025 (Estimated)
ATRA Atara Biotherapeutics	-$85.40M	-$0.43	N/A	N/A	N/A	3.07%	-8.34%	6.61%	11/11/2025 (Estimated)
BCAB BioAtla	-$69.78M	-$1.10	N/A	N/A	N/A	N/A	-1,177.18%	-137.51%	11/6/2025 (Estimated)

Latest BCAB, ATRA, ABOS, and ANRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ANRO Alto Neuroscience	-$0.57	-$0.65	-$0.08	-$0.65	N/A	N/A
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/11/2025	Q2 2025	ATRA Atara Biotherapeutics	-$0.32	$0.19	+$0.51	$0.19	$4.23 million	$17.58 million
8/7/2025	Q2 2025	BCAB BioAtla	-$0.29	-$0.31	-$0.02	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
BCAB BioAtla	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.26	5.97	5.97
ANRO Alto Neuroscience	0.18	18.43	18.43
ATRA Atara Biotherapeutics	N/A	1.70	1.70
BCAB BioAtla	N/A	1.24	1.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
ANRO Alto Neuroscience	N/A
ATRA Atara Biotherapeutics	70.90%
BCAB BioAtla	77.23%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
ANRO Alto Neuroscience	11.13%
ATRA Atara Biotherapeutics	4.00%
BCAB BioAtla	11.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	54.94 million	Optionable
ANRO Alto Neuroscience	N/A	27.08 million	24.06 million	N/A
ATRA Atara Biotherapeutics	330	7.02 million	6.74 million	Optionable
BCAB BioAtla	60	58.72 million	52.13 million	Optionable

BCAB, ATRA, ABOS, and ANRO Headlines

Recent News About These Companies

BioAtla (NASDAQ:BCAB) Stock Price Up 1.4% - Here's What Happened

August 21 at 3:43 AM | americanbankingnews.com

BioAtla (NASDAQ:BCAB) Cut to "Market Perform" at Citizens Jmp

August 16, 2025 | americanbankingnews.com

HC Wainwright Has Negative Outlook for BioAtla Q3 Earnings

August 15, 2025 | americanbankingnews.com

JMP Securities Reiterates "Market Perform" Rating for BioAtla (NASDAQ:BCAB)

August 15, 2025 | americanbankingnews.com

JMP Securities Downgrades BioAtla (BCAB)

August 14, 2025 | msn.com

BioAtla downgraded to Market Perform from Outperform at Citizens JMP

August 13, 2025 | msn.com

BioAtla’s Earnings Call: Positive Clinical Progress Amid Financial Challenges

August 13, 2025 | msn.com

BioAtla, Inc. (NASDAQ:BCAB) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress

August 8, 2025 | finance.yahoo.com

BioAtla (BCAB) Q2 Loss Narrows 27%

August 8, 2025 | aol.comA

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

August 4, 2025 | globenewswire.com

BioAtla Stock Short Interest Report | NASDAQ:BCAB - Benzinga

July 29, 2025 | benzinga.com

BioAtla, Inc. (BCAB) latest stock news and headlines - Yahoo Finance

July 18, 2025 | uk.finance.yahoo.com

BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting

July 17, 2025 | globenewswire.com

BioAtla Reports Encouraging Preliminary Results from Phase 1 Study of BA3182 in Heavily Pretreated Metastatic Adenocarcinoma Patients - Nasdaq

July 5, 2025 | nasdaq.com

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress

July 3, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/07/03/3109806/0/en/bioatla-presents-data-from-ongoing-dose-escalation-of-ba3182-dual-conditionally-binding-epcam-x-cd3-bispecific-t-cell-engager-in-patients-with-treatment-refractory-metastatic-adeno.html$

BCAB - BioAtla Inc Ordinary Shares Ownership - Morningstar

July 1, 2025 | morningstar.comM

BioAtla Approves 2025 Corporate Bonus Plan

June 20, 2025 | tipranks.com

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma ...

June 3, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB, ATRA, ABOS, and ANRO Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.53 +0.17 (+12.50%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.52 -0.01 (-0.33%)

As of 08/22/2025 07:55 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Alto Neuroscience NYSE:ANRO

$3.91 +0.32 (+8.83%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$3.90 -0.01 (-0.18%)

As of 08/22/2025 06:35 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Atara Biotherapeutics NASDAQ:ATRA

$12.34 +0.85 (+7.40%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$12.39 +0.05 (+0.41%)

As of 08/22/2025 06:19 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

BioAtla NASDAQ:BCAB

$0.36 0.00 (-0.39%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.37 +0.01 (+3.03%)

As of 08/22/2025 07:28 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time